Patents by Inventor William E. Pierceall

William E. Pierceall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for determining chemosensitivity and chemotoxicity
    Patent number: 11519015
    Abstract: The present disclosure relates to diagnostic methods that are relevant to various cancers and which comprise BH3 profiling diagnostics for, among others, predication of an adverse patient response to a cancer treatment.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: December 6, 2022
    Assignee: Entropics Pharmaceuticals, Inc.
    Inventors: William E. Pierceall, Michael H. Cardone
  • COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS
    Publication number: 20220378722
    Abstract: The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).
    Type: Application
    Filed: May 4, 2022
    Publication date: December 1, 2022
    Inventors: Mark D. DEMARIO, Tamara MAES, William E. PIERCEALL, Fiona MACK, Serena LUNARDI
  • METHODS FOR DETERMINING CHEMOSENSITIVITY AND CHEMOTOXICITY
    Publication number: 20200283819
    Abstract: The present disclosure relates to diagnostic methods that are relevant to various cancers and which comprise BH3 profiling diagnostics for, among others, predication of an adverse patient response to a cancer treatment.
    Type: Application
    Filed: March 24, 2020
    Publication date: September 10, 2020
    Inventors: William E. PIERCEALL, Michael H. CARDONE
  • Methods for determining chemosensitivity and chemotoxicity
    Patent number: 10640803
    Abstract: The present disclosure relates to diagnostic methods that are relevant to various cancers and which comprise BH3 profiling diagnostics for, among others, predication of an adverse patient response to a cancer treatment.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: May 5, 2020
    Assignee: Eutropics Pharmaceuticals, Inc.
    Inventors: William E. Pierceall, Michael H. Cardone
  • PHARMACODYNAMIC BIOMARKERS FOR PERSONALIZED CANCER CARE USING EPIGENETIC MODIFYING AGENTS
    Publication number: 20190256929
    Abstract: The invention provides methods of monitoring differential gene expression of pharmacodynamic (PD) biomarkers in patients treated with Lysine Demethylase 1 (LSD 1) inhibitors and methods of determining the sensitivity of a cell to an LSD 1 inhibitor by measuring PD biomarkers.
    Type: Application
    Filed: November 2, 2017
    Publication date: August 22, 2019
    Inventors: Fabian BIRZELE, Wei-Yi CHENG, Mark D. DEMARIO, Fiona MACK, Francesca MILLETTI, William E. PIERCEALL
  • GENE EXPRESSION BIOMARKERS FOR PERSONALIZED CANCER CARE TO EPIGENETIC MODIFYING AGENTS
    Publication number: 20190153538
    Abstract: The present application discloses a method to predict responsiveness of a patient, with cancer, to treatment with LSD1 inhibitors, said method comprising measuring mRNA expression levels of one or more genes selected from the list of ASCL1, DDC, CEACAM6, LRRIQ4, NR0B2, GRP, CEACAM5, SOX21, OR51E2, SEC11C, BAALC, CCDC40, RAB3B, RGS17, ABCE1, ETS2, CCDC154, SPAG6, PON1, TMEM176A, C1orf127, IGF2BP2, IGFBP5, FAM84A, FOXA2, HOXA10, NCAM1, NCAM2, NEUROD1, KRT8, ENO2, AVP, OXT, SYP, CHGA, CHGB, BCL2 and MYC.
    Type: Application
    Filed: October 8, 2016
    Publication date: May 23, 2019
    Inventors: Wei-Yi CHENG, Mark D. DEMARIO, Fiona MACK, Francesca MILLETTI, William E. PIERCEALL
  • Combinations of LSD1 inhibitors for use in the treatment of solid tumors
    Patent number: 10265279
    Abstract: The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: April 23, 2019
    Assignee: Oryzon Genomics, S.A.
    Inventors: Mark D. Demario, Tamara Maes, William E. Pierceall, Fiona Mack, Serena Lunardi
  • SURROGATE FUNCTIONAL DIAGNOSTICS TEST FOR CANCER
    Publication number: 20180246106
    Abstract: The present invention relates to diagnostic methods that are relevant to various cancers and which comprise improvements on a BH3 profiling diagnostic method.
    Type: Application
    Filed: November 3, 2017
    Publication date: August 30, 2018
    Inventors: William E. PIERCEALL, Michael H. CARDONE
  • COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS
    Publication number: 20170281567
    Abstract: The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).
    Type: Application
    Filed: March 14, 2017
    Publication date: October 5, 2017
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Mark D. DEMARIO, Tamara MAES, William E. PIERCEALL, Fiona MACK, Serena LUNARDI
  • METHODS FOR PERSONALIZING PATIENT CANCER THERAPY WITH AN MDM2 ANTAGONIST
    Publication number: 20170227544
    Abstract: The present application discloses a method to predict responsiveness of a patient, with cancer, to treatment with an MDM2 antagonist of formulae I, II and III as disclosed herein, said method comprising a multivariate analysis comprising detecting relative amounts of certain MDM2 protein expressing cells and, optionally additional co-variates selected from a gene signature as disclosed herein, p53 mutation status, the patient's age and ECOG score at baseline as a biomarker for predicting said patient's response to treatment.
    Type: Application
    Filed: October 7, 2015
    Publication date: August 10, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Steven D. Blotner, Gong Chen, Lori Jukofsky, Gwen Nichols, William E. Pierceall, Bernhard Reis, Ruediger Rueger, Hua Zhong
  • METHODS FOR DETERMINING CHEMOSENSITIVITY AND CHEMOTOXICITY
    Publication number: 20160273020
    Abstract: The present disclosure relates to diagnostic methods that are relevant to various cancers and which comprise BH3 profiling diagnostics for, among others, predication of an adverse patient response to a cancer treatment.
    Type: Application
    Filed: October 30, 2014
    Publication date: September 22, 2016
    Inventors: William E. PIERCEALL, Michael H. Cardone
  • Biomarkers For The Identification, Monitoring, And Treatment Of Non-Small Cell Lung Cancer (NSCLC)
    Publication number: 20110217713
    Abstract: This present invention compositions and methods of treating, diagnosing, prognosing cancer and methods of accessing/monitoring the responsiveness of a cancer cell to a therapeutic compound.
    Type: Application
    Filed: March 7, 2011
    Publication date: September 8, 2011
    Applicant: On-Q-ity
    Inventors: David T. Weaver, William E. Pierceall, Brian Ward